Goodwin‘s group has a strong reputation for its patent prosecution work in the life sciences and tech sectors in particular. The team is also equipped to assist across pharma, medical devices, and tech among other sectors, advising on patent matters covering clearance, patentability, infringement, and validity, among other areas. The team is helmed by Boston-based Catherine McCarty and James Riley, who works from Silicon Valley. A life sciences expert with a specialism in drug development, Theresa Kavanaugh is a key name in Boston. Carl Morales joined the New York office from Fenwick & West LLP in January 2025.
Legal 500 Editorial commentary
Key clients
- Impulse Labs
- Moon Five Technologies
- Illumina, Inc.
- Xaira Therapeutics
- Insitro
- Mission Bio
- FidoCure
- Particella, Inc.
- Allurion Technologies
- Shennon Biotechnologies
Work highlights
- Advised insitro, Inc. on its strategic collaboration with Gilead Sciences Inc. to discover and develop therapies for patients with nonalcoholic steatohepatitis (NASH), with up to $50m in near-term payments and $1bn in deal value.
- Advised Xaira Therapeutics, Inc. on the IP aspects for its $1bn in committed funding.
- Advised Deciphera Pharmaceuticals on the IP aspects of its definitive agreement under which ONO Pharmaceutical Co., Ltd. will acquire Deciphera for $25.60 per share in cash, which represents a total equity value of $2.4bn.
Lawyers
Practice head
Catherine McCarty; James Riley
Other key lawyers
Carl Morales; Theresa Kavanaugh; Michael Shuster